Health
Maker seeking Indian trial of Novavax jab – 7NEWS.com.au
Vaccine maker, the Serum Institute of India, wants to trial the Novavax jab locally, to factor in genetic differences in its population.
The Serum Institute of India, the world’s biggest vaccine maker, has applied to local authorities to conduct a small domestic trial of Novavax Inc’s COVID-19 vaccine, which was found to be 89.3 per cent effective in a UK trial.
Serum expected a decision on an Indian trial of Novavax’s vaccine soon, Chief Executive Adar Poonawalla told Reuters on Friday, hours after the US company reported the efficacy data.
“We have already applied to the drug controller’s office for the bridging trial, a few days…
-
Business21 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News20 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General15 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News17 hours agoTips to improve engagement – Proctor